Palabras clave
Hanseníase
Dapsona
Genética
Farmacogenética
Terapêutica
Dapsona
Genética
Farmacogenética
Terapêutica
Cómo citar
1.
BEIGUELMAN B. Terapêutica da lepra e farmacogenética. Hansen. Int. [Internet]. 30 de junio de 1976 [citado 21 de noviembre de 2024];1(1):61-78. Disponible en: https://periodicos.saude.sp.gov.br/hansenologia/article/view/35676
Resumen
No presente trabalho foram analisadas algumas características farmacogeneticas que são polimorfismos genéticos humanos e que influenciam a ação da 4,4'-diaminodifenilsulfona (DDS), o medicamento mais amplamente empregado na terapêutica da lepra. Deu-se atenção especial aos polimorfismos da acetiltransferase, da desidrogenase de 6-fosfato de glicose e da NADH redutase de metemoglobina. Além da revisão e análise critica da literatura, foram apresentadas sugestões para novas investigações.
Citas
1. ALEXANDER, J. O. Dapsone in the treatment of dermatitis herpetiformis. Lancet, 268(6876) :1201-1202, 1955.
2. ALLDAY, E. J. & BARNES, J. Toxic effects of diaminodiphenylsulphone in the treatment of leprosy. Lancet, 261(6675) :205-206, 1951.
3. ALLISON, A. C. & REES, W. The binding of haemoglobin by plasma proteins (haptoglobins). Its bearing on the "renal threshold" for haemoglobin and the aethiology of haemoglobinuria. Br. Med. J., (5054) :1137-1143, 1957.
4. BECHELLI, L. M. Leprosy today. World Health: 10-19, Oct. 1971.
5. BECHELLI, L. M. & MARTINEZ-DOMINGUEZ, V. The Leprosy problem in the world. Bull. World Health Organ., 34:811-826, 1966.
6. BEIGUELMAN, B. Reação gustativa b. fenil-tio-carbamida (PTC) e lepra. Rev. Bras. Leprol., 30:111-124, 1962.
7. BEIGUELMAN, B. Taste sensitivity to phenylthiourea among patients affected with both tuberculosis and leprosy. Acta Genet. Med. Gemellol., 13(2): 190-192, 1964.
8. BEIGUELMAN, B. Taste sensitivity to phenylthiourea and leprosy. Acta Genet. Med. Gemellol., 13(2) :193-196, 1964.
9. BEIGUELMAN, B. & MARQUES, M. B. Taste sensitivity to phenylthiourea and drugs with antileprotic effect. Acta Genet. Med. Gemellol., 13(2): 200-202, 1964.
10. BEIGUELMAN, B.; PINTO JR., W.; DALL'AGLIO, F. F.; SILVA, E.; VOZZA, J. A. Deficiência da desidrogenase de 6-fosfato de glicose (G-6PD) e lepra. In: REUNIÃO ANUAL DA SBPC, 18.°, Blumenau, SC, 1966. Resumo das comunicagdes.[s.n.t.] apud Ciência e Cultura, 18(2) :95-96, 1966.
11. BEIGUELMAN, B.; PINTO JR., W.; DALL'AGLIO, F. F.; SILVA, E.; VOZZA, J. A. G-6PD deficiency among lepers and healthy people in
Brazil. Acta Genet., (Basel), 18:159-162, 1968.
12. BEIGUELMAN, B.; PINTO JR., W.; EL-GUINDY, M. M.; KRIEGER, H. Factors influencing the level of DDS in blood. Bull. World Health Organ., 51:467-471, 1974.
13. BELDA, W. Resultados preliminares no tratamento da reação hansênica com o dextrosulfenidol. Rev. Bras. Leprol., 37(1/4) :5-16, 1970.
14. BRUCE-CHWATT, L. J. Changing tides of chemotherapy of malaria. Brit. Med. J., 1(5383) :581-586, 1964.
15. COCHRANE, R. G. Critical review of present position of sulfone therapy in leprosy. Trans. Roy. Soc. Trop. Med. Hyg., 44:259-270, 1950.
16. COHEN, R. J.; SACHS, J. R.; WICKER, D. J.; CONRAD, M. E. Methemo- globinemia provoked by malarial chemoprophylaxis in Vietnam. New Engl. J. Med., 279(21) :1127-1131, 1968.
17. CONVIT, J.; BROWNE, S. G.; LANGUILLON, J.• PETTIT, J. H. S.• RAMA- NUJAM, K.; SAGHER, F.; SHESKIN, J.-' SOUZA-LIMA, L.•' TARABINI, G.; TOLENTINO, J. G.; WATERS, IW. F. R.; BECHELLI, L. M.; MAR- TINEZ-DOMINGUEZ, V. Therapy of leprosy. Bull. World Health Or- gan., 42(5) :667-672, 1970.
18. DeGOWIN, R. L. A review of therapeutic and hemolytic effects of dapsone. Arch. Intern. Med., 120:242-248, 1967.
19. DeGOWIN, R. L.; EPPES, R. B.; POWELL, R. D.; CARSON, P. E. The haemolytic effects of diaphenylsulfone (DDS) in normal subjects and in those with glucose-6-phosphate-dehydrogenase deficiency. Bull. World Health Organ., 35(2) :165-179, 1967.
20. DESFORGES, J. F.; THAYER, W. W.•' DAWSON, J. P. Hemolytic anemia induced by sulfoxone therapy, with investigation into the mechanisms of its production. Am. J. Med., 27:132-136, 1959.
21. ELLARD, G. A.; GAMMON, P. T.; HELMY, H. S.; REES, R. J. W. Dapsone acetylation and the treatment of leprosy. Nature, 239:159-160, 1972.
22. EVANS, D. A. P.• MANLEY, K. A.; McKUSICK, V. A. Genetic control of isoniazid metabolism in man. Br. Med. J., 1 (5197) :485-491, 1960.
23. EVANS, D. A. P. & WHITE, T. A. Human acetvlation polymorphism. J. Lab. Clin. Med., 68:394-403, 1964.
24. FABRO, S.; SHUMACHER, H.; SMITH, R. L.; STAGG, R. B. L.; WILLIAMS, R. T. The metabolism of thalidomide: some biological effects of thalido- mide and its metabolites. Br. J. Pharmacol., 25:352-362, 1965.
25. GELBER, R.; PETERS, J. H.; GORDON, G. R.; GLAZKO, A. J.; LEVY, L. The polymorphic acetylation of dapsone in man. Clin. Pharmacol. The- rapeut., 12:225-238, 1971.
26. GILLES, H. 1W. & TAYLOR, B. G. The existence of the glucose-6-phosphate dehydrogenase deficiency trait in Nigeria and its clinical implications. Ann. Trop. Med. Parasitol., 55:64-69, 1961.
27. HARRIS, H. & KALMUS, H. Chemical specificity in genetical differences of taste sensitivity. Ann. Eugen., 15:32-45, 1949.
28. HJELM, M. & VERDIER, C. H. D. Biochemical effects of aromatic amines. I. Methaemoglobinaemia, heamolysis and Heinz-body formation induced by 4,4'- diaminodiphenylsulphone. Biochem. Pharmacol., /4:1119-1128, 1965.
29. HOPKINS, C. Y. A sulphur containing substance from the seed of Coringia Orientalis. Canad. J. Res. B., 16:341-344, 1938.
30. HOPKINS, C. Y. Taste differences in compounds having NCS linkage. Canad. J. Res. B., 20:268-273 ,1942.
31. IYER, C. G. S.; LANGUILLON, J.; RAMANUJAM, K.; TARABINI-CAS- TELLANI, G.; TERENCIO DE LAS AGUAS, J.; BECHELLI, L. M.; UEMURA, K.; MARTINEZ DOMINGUEZ, V.; SUNUARESAN, T. Who co-ordinated short-term double-blind trial with thalidomide in the treatment of acute lepra reactions in male lepromatous patients. Bull. World Health Organ., 45:719-732, 1971.
32. JELLIFFE, D. B. Toxic hepatitis caused by diaminocliphenyl-sulphone. Lancet, 260(6670) :1343-1344, 1951.
33. KNIGHT, R. A.; SELIN, M. J.; HARRIS, H. W. Genetic factors influencing isoniazid blood levels in humans. In: CONFERENCE ON CHEMOTHE- RAPY OF TUBERCULOSIS, 18th, Washington, D.C., 1959. Transactions. p.52.
34. LANGUILLON, J. & LINHARD, J. Research on association between genetic factors and leprosy in Africa. In: INTERNATIONAL LEPROSY CON- GRESS, 10th, Bergen, 1973. Transactions apud Int. J. Leprosy, 41(4): 603, 1973.
35. LECHAT, M. F.; BIAS, W. B.; BLUMBERG, B. S.; MELARTIN, L.; QUINTO, R. S.; COHEN, B. H.; TOLENTINO, J. G.; ABALOS, R. M. A con- trolled study of polyraorphisms in serum globulin and glucose-6-phosphate dehydrogenase deficiency in leprosy. Int. J. Leprosy, 36(2) :179-191, 1968.
36. LEIKER, D. L. The mononucleosis syndrome in leprosy patients treated with sulfones. Int. J. Leprosy, 24(4) :402-405, 1966.
37. LEIKER, D. L. & KAMP, H. First results of treatment of leprosy with rifadin. Lepr. Rev., 41(1) :25-30, 1970.
38. LEWGOY, F. & SALZANO, F. M. Dinâmica do gen que condiciona a de- ficiência em G-6-PD na população de Porto Alegre. In: REUNIÃO ANUAL DA SBPC, 17ª, Belo Horizonte, M.G., 1966. Resumo das comunicações. [s.n.t.] apud Ciência e Cultura, 17(2): 152, 1965.
39. LINCOLN, E. M.; STONE, S.; HOFFMAN, O. R. The treatment of miliary tuberculosis with promizole. Bull. Johns Hopkins Hosp., 82:56-75, 1948.
40. LINN, H. W. The use of dapsone in dermatology. Aust. J. Derm., 6:203-207, 1962.
41. LORINCZ, A. L. & PEARSON, R. W. Sulfapyridine and sulfone type drugs in dermatology. Arch. Dermatol., 85(1) :2-16, 1962.
42. MARQUES, M. B. & OPROMOLLA, D. V. A. A talidomida no tratamento da reação leprótica. Rev. Bras. Leprol., 37(1/4) :41-49, 1970.
43. McRAE, D. H.; RUSSEL, D. A.; SCOTT, G. C.; VINCIN, D. R.; SHEPARD, C. C. Four year results in the therapeutic trial of acedapsone (DADDS) in the Karimui, New Guinea. Int. J. Leprosy, 40(2) :222-223, 1972.
44. MENON, N. K. Madras study of two once-weekly regimens. Clinical aspects. Proc. Int. Tuberc. Conf., (New York, 1969). Bull. Int. Union Against Tuberc., 43:271-275, 1970.
45. MIGUEZ ALONSO, A. Tratamento especifico. In: BRASIL. Ministério da Saúde. Serviço Nacional de Lepra. Manual de Leprologia. Rio de Ja- neiro, 1960. p.97-118.
46. MOLESWORTH, B. D.; NARAYANASWAMI, P. S.; SIMPSON, I. A. The treatment of lepromatous leprosy with 4:4'-diaminodiphenyl sulfone in oil: findings in 100 cases treated for one year' with a note on the technique of sulfone determinations. Int. J. Leprosy. 17(3) :197-210, 1949.
47. MOTULSKY, A. G. Pharmacogenetics. Progr. Med. Genet., 3:49-74, 1964.
48. ORGANISATION MONDIALE DE LA SANTA. Série de Rapports Techniques. Resistance des parasites du paludisme aux medicaments. Rapport d'un Groupe scientifique de l'OMS. Genève, n.° 296, 1965.
49. ORGANIZACIÓN MUNDIAL DE LA SALUD. Serie de Informes Técnicos. Farmacogenetica. Informe de un Grupo Cientifico de la OMS. Genebra, n.° 524, 1973.
50. OPROMOLLA, D. V. A. First results of the use of rifamycin SV in the treatment of lepromatous leprosy. hit. J. Leprosy, 31 :552, 1963.
51. OPROMOLLA, D. V. A. & ALMEIDA, S. C. Primeiros resultados do trata- mento da lepra com kanamicina. Rev. Bras. Leprol., 37(1/4) :17-39, 1970.
52. OPROMOLLA, D. V. A.; PESSOA-MENDES, J.; SOUZA-LIMA, L. A terra- micina na lepra. Rev. Bras. Leprol., 38(1/4) :1-21, 1965.
53. OPROMOLLA, D. V. A.; SOUZA-LIMA, L.; CAPRARA, G. Rifamycin SV in the treatment of lepromatous leprosy. Lepr. Rev., 86(3) :123-131, 1966.
54. OWEN, J. A.; MACKAY, I. R.; GOT, C. Serum haptoglobins in hepatobiliary disease. Br. Med. J., (5135) :1454-1457, 1959.
55. PETERS, J. H.; GORDON, G. R.; BROWN, P. The relationship between the capacities of human subjects to acetylate isoniazid, sulfanilamide and sulfamethazine. Life Sol., 4:99-107, 1965.
56. PETERS, J. H.; GORDON, G. R.; GHOUL, D. C.; TOLENTINO, J. G.; WALSH, G. P.; LEVY,L. The disposition of the antileprotic drug dapsone (DDS) in Philippine subjets. Am. J. Trop. Med. Hyg., 21:450-457, 1972.
57. PETERS, J. H.; GORDON, G. R.; KARAT, A. B. A.; MEYERS, W. M. Metabolic disposition of dapsone in Indian and African subjects. In: ANNUAL LEPROSY RESEARCH CONFERENCE, 7th, California, 1972 apud Int. J. Leprosy, 40(2) :221-222, 1972.
58. PETERS, J. H.; GORDON, G. R.; LEVY, L.; STORKAN, M. A.; JACOBSON, R. R.; ENNA, C. D.; KIRCHHEIMER, W. F. Metabolic disposition of dapsone in patients with dapsone-resistant leprosy. Am. J. Trop. Med. Hyg., 23:222-230, 1972.
59. PETTIT, J. H. S. & CHIN, J. Does glucose-6-phosphate dehydrogenase defi- ciency modify the course of leprosy or its treatment. Lepr. Rev., 35(4): 149-156, 1964.
60. POVEY, M. S. & HORTON, R. J. Leprosy and blood groups. Lepr. Rev. 37:147-150, 1966.
61. RAMOS E SILVA, J. Sur le traitement de la 16pre, en particulier de l'hypodermite nodulaire lepromateuse recidivante par la griseofulvine. Dermat. Internat., 7:37-42, 1968 apud /nt. J. Leprosy, 37:208, 1969.
62. BEES, R. J. W. Rifampicin as therapy in lepromatous leprosy. Star, 33 (4): 5, 12, 1974.
63. REES, R. J. W.; PEARSON, J. M. H.; WATERS, M. F. R. Experimental and clinical studies on rifampicin in the treatment of leprosy. Br. Med. J., 1:89-92, 1970.
64. SCHWANTES, A. R.; SALZANO, F. M.; CASTRO, I. V.; TONDO, C. V. Haptoglobins and leprosy. Acta Genet. (Basel), 17:127-136, 1967.
65. SHEPARD, C. C. The first decade in experimental leprosy. Bull. World Health Organ., 44(6) :821-827, 1971.
66. SHESKIN, J. Further observation with thalidomide in lepra reactions. Lepr. Rev., 36:183-187, 1965.
67. SLOAN, N. R.; JANO, B.; WORTH, R. M.; FASAL, P.•' SHEPARD, C. C. Repository acedapsone in leprosy chemoprophylaxis and treatment. Lancet, 2:525-526, 1971.
68. SOUZA-LIMA, L. Considerageies sobre o real valor da sulfonoterapia nos pro- gramas de profilaxia da lepra. Rev. Bras. Leprol., 86(1/4) :31-36, 1968/ 1969.
69. SUNAHARA, S.; URANO, M.; LIN, H. T.; CHEG, T. J.•' JARUMILINDA, A. Further observations on trimodality of frequency distribution curve of bio- logically ative isoniazid blood levels and 'cline' in frequencies of alleles controlling isoniazid inactivation. Acta Tuberc. Pneumol. Scand., 43 :181- 195, 1963.
70. SUNAHARA, S.; URANO, M.; OGAWA, M. Genetical and geographic studies on isoniazid inactivation. Science, 134:1530-1531, 1961.
71. TAUSSIG, H. B. A study of the German outbreak of phocomelia. The tha- lidomide syndrome. J. Amer. med. Ass., /80:1106-1113, 1962.
72. TUBERCULOSIS CHEMOTHERAPY CENTRE, Madras. A controlled comparison of a twice-weekly and three once-weekly regimens in the initial treatment of pulmonary tuberculosis. Bull. World Health Organ., 48(1): 143-206, 1970.73. VESELL, E. S. Recent progress in pharmacogenetics. Adv. Pharmacol. Chemother., 7:1-52, 1969.
74. WEINSTEIN, L. Medicamentos utilizados na quimioterapia da lepra e da tuberculose. In: GOODMAN, L. S. & GILMAN, A., ed. As bases farmacológicas da terapêutica. [trad. de Lauro SoHero] 4.a ed. Rio de Janeiro, Guanabara Koogan, 1973. cap. 61, p. 1211-1241.
75. WOLF, M. Dermatitis herpetiformis: response to diaminodiphenylsulfone. Arch. Derm,atol., 82(6) :1020-1021, 1960.
76. WORLD HEALTH ORGANIZATION. Technical Report Series. WHO expert committee on leprosy. Fourth report. Geneva, n.° 459, 1970.
77. YOSHIDA, A. Hemolytic anemia and G6PD deficiency. Science, 179 :532- 537, 1973.
78. ZINKHAM, W. H.; LENHARD JR., R. E.; CHILDS, B. Deficiency of glucose 6-phosphate dehydrogenase activity in erythrocytes from patients with favism. Bull. Johns Hopkins Hosp., 102:169-175, 1958.
2. ALLDAY, E. J. & BARNES, J. Toxic effects of diaminodiphenylsulphone in the treatment of leprosy. Lancet, 261(6675) :205-206, 1951.
3. ALLISON, A. C. & REES, W. The binding of haemoglobin by plasma proteins (haptoglobins). Its bearing on the "renal threshold" for haemoglobin and the aethiology of haemoglobinuria. Br. Med. J., (5054) :1137-1143, 1957.
4. BECHELLI, L. M. Leprosy today. World Health: 10-19, Oct. 1971.
5. BECHELLI, L. M. & MARTINEZ-DOMINGUEZ, V. The Leprosy problem in the world. Bull. World Health Organ., 34:811-826, 1966.
6. BEIGUELMAN, B. Reação gustativa b. fenil-tio-carbamida (PTC) e lepra. Rev. Bras. Leprol., 30:111-124, 1962.
7. BEIGUELMAN, B. Taste sensitivity to phenylthiourea among patients affected with both tuberculosis and leprosy. Acta Genet. Med. Gemellol., 13(2): 190-192, 1964.
8. BEIGUELMAN, B. Taste sensitivity to phenylthiourea and leprosy. Acta Genet. Med. Gemellol., 13(2) :193-196, 1964.
9. BEIGUELMAN, B. & MARQUES, M. B. Taste sensitivity to phenylthiourea and drugs with antileprotic effect. Acta Genet. Med. Gemellol., 13(2): 200-202, 1964.
10. BEIGUELMAN, B.; PINTO JR., W.; DALL'AGLIO, F. F.; SILVA, E.; VOZZA, J. A. Deficiência da desidrogenase de 6-fosfato de glicose (G-6PD) e lepra. In: REUNIÃO ANUAL DA SBPC, 18.°, Blumenau, SC, 1966. Resumo das comunicagdes.[s.n.t.] apud Ciência e Cultura, 18(2) :95-96, 1966.
11. BEIGUELMAN, B.; PINTO JR., W.; DALL'AGLIO, F. F.; SILVA, E.; VOZZA, J. A. G-6PD deficiency among lepers and healthy people in
Brazil. Acta Genet., (Basel), 18:159-162, 1968.
12. BEIGUELMAN, B.; PINTO JR., W.; EL-GUINDY, M. M.; KRIEGER, H. Factors influencing the level of DDS in blood. Bull. World Health Organ., 51:467-471, 1974.
13. BELDA, W. Resultados preliminares no tratamento da reação hansênica com o dextrosulfenidol. Rev. Bras. Leprol., 37(1/4) :5-16, 1970.
14. BRUCE-CHWATT, L. J. Changing tides of chemotherapy of malaria. Brit. Med. J., 1(5383) :581-586, 1964.
15. COCHRANE, R. G. Critical review of present position of sulfone therapy in leprosy. Trans. Roy. Soc. Trop. Med. Hyg., 44:259-270, 1950.
16. COHEN, R. J.; SACHS, J. R.; WICKER, D. J.; CONRAD, M. E. Methemo- globinemia provoked by malarial chemoprophylaxis in Vietnam. New Engl. J. Med., 279(21) :1127-1131, 1968.
17. CONVIT, J.; BROWNE, S. G.; LANGUILLON, J.• PETTIT, J. H. S.• RAMA- NUJAM, K.; SAGHER, F.; SHESKIN, J.-' SOUZA-LIMA, L.•' TARABINI, G.; TOLENTINO, J. G.; WATERS, IW. F. R.; BECHELLI, L. M.; MAR- TINEZ-DOMINGUEZ, V. Therapy of leprosy. Bull. World Health Or- gan., 42(5) :667-672, 1970.
18. DeGOWIN, R. L. A review of therapeutic and hemolytic effects of dapsone. Arch. Intern. Med., 120:242-248, 1967.
19. DeGOWIN, R. L.; EPPES, R. B.; POWELL, R. D.; CARSON, P. E. The haemolytic effects of diaphenylsulfone (DDS) in normal subjects and in those with glucose-6-phosphate-dehydrogenase deficiency. Bull. World Health Organ., 35(2) :165-179, 1967.
20. DESFORGES, J. F.; THAYER, W. W.•' DAWSON, J. P. Hemolytic anemia induced by sulfoxone therapy, with investigation into the mechanisms of its production. Am. J. Med., 27:132-136, 1959.
21. ELLARD, G. A.; GAMMON, P. T.; HELMY, H. S.; REES, R. J. W. Dapsone acetylation and the treatment of leprosy. Nature, 239:159-160, 1972.
22. EVANS, D. A. P.• MANLEY, K. A.; McKUSICK, V. A. Genetic control of isoniazid metabolism in man. Br. Med. J., 1 (5197) :485-491, 1960.
23. EVANS, D. A. P. & WHITE, T. A. Human acetvlation polymorphism. J. Lab. Clin. Med., 68:394-403, 1964.
24. FABRO, S.; SHUMACHER, H.; SMITH, R. L.; STAGG, R. B. L.; WILLIAMS, R. T. The metabolism of thalidomide: some biological effects of thalido- mide and its metabolites. Br. J. Pharmacol., 25:352-362, 1965.
25. GELBER, R.; PETERS, J. H.; GORDON, G. R.; GLAZKO, A. J.; LEVY, L. The polymorphic acetylation of dapsone in man. Clin. Pharmacol. The- rapeut., 12:225-238, 1971.
26. GILLES, H. 1W. & TAYLOR, B. G. The existence of the glucose-6-phosphate dehydrogenase deficiency trait in Nigeria and its clinical implications. Ann. Trop. Med. Parasitol., 55:64-69, 1961.
27. HARRIS, H. & KALMUS, H. Chemical specificity in genetical differences of taste sensitivity. Ann. Eugen., 15:32-45, 1949.
28. HJELM, M. & VERDIER, C. H. D. Biochemical effects of aromatic amines. I. Methaemoglobinaemia, heamolysis and Heinz-body formation induced by 4,4'- diaminodiphenylsulphone. Biochem. Pharmacol., /4:1119-1128, 1965.
29. HOPKINS, C. Y. A sulphur containing substance from the seed of Coringia Orientalis. Canad. J. Res. B., 16:341-344, 1938.
30. HOPKINS, C. Y. Taste differences in compounds having NCS linkage. Canad. J. Res. B., 20:268-273 ,1942.
31. IYER, C. G. S.; LANGUILLON, J.; RAMANUJAM, K.; TARABINI-CAS- TELLANI, G.; TERENCIO DE LAS AGUAS, J.; BECHELLI, L. M.; UEMURA, K.; MARTINEZ DOMINGUEZ, V.; SUNUARESAN, T. Who co-ordinated short-term double-blind trial with thalidomide in the treatment of acute lepra reactions in male lepromatous patients. Bull. World Health Organ., 45:719-732, 1971.
32. JELLIFFE, D. B. Toxic hepatitis caused by diaminocliphenyl-sulphone. Lancet, 260(6670) :1343-1344, 1951.
33. KNIGHT, R. A.; SELIN, M. J.; HARRIS, H. W. Genetic factors influencing isoniazid blood levels in humans. In: CONFERENCE ON CHEMOTHE- RAPY OF TUBERCULOSIS, 18th, Washington, D.C., 1959. Transactions. p.52.
34. LANGUILLON, J. & LINHARD, J. Research on association between genetic factors and leprosy in Africa. In: INTERNATIONAL LEPROSY CON- GRESS, 10th, Bergen, 1973. Transactions apud Int. J. Leprosy, 41(4): 603, 1973.
35. LECHAT, M. F.; BIAS, W. B.; BLUMBERG, B. S.; MELARTIN, L.; QUINTO, R. S.; COHEN, B. H.; TOLENTINO, J. G.; ABALOS, R. M. A con- trolled study of polyraorphisms in serum globulin and glucose-6-phosphate dehydrogenase deficiency in leprosy. Int. J. Leprosy, 36(2) :179-191, 1968.
36. LEIKER, D. L. The mononucleosis syndrome in leprosy patients treated with sulfones. Int. J. Leprosy, 24(4) :402-405, 1966.
37. LEIKER, D. L. & KAMP, H. First results of treatment of leprosy with rifadin. Lepr. Rev., 41(1) :25-30, 1970.
38. LEWGOY, F. & SALZANO, F. M. Dinâmica do gen que condiciona a de- ficiência em G-6-PD na população de Porto Alegre. In: REUNIÃO ANUAL DA SBPC, 17ª, Belo Horizonte, M.G., 1966. Resumo das comunicações. [s.n.t.] apud Ciência e Cultura, 17(2): 152, 1965.
39. LINCOLN, E. M.; STONE, S.; HOFFMAN, O. R. The treatment of miliary tuberculosis with promizole. Bull. Johns Hopkins Hosp., 82:56-75, 1948.
40. LINN, H. W. The use of dapsone in dermatology. Aust. J. Derm., 6:203-207, 1962.
41. LORINCZ, A. L. & PEARSON, R. W. Sulfapyridine and sulfone type drugs in dermatology. Arch. Dermatol., 85(1) :2-16, 1962.
42. MARQUES, M. B. & OPROMOLLA, D. V. A. A talidomida no tratamento da reação leprótica. Rev. Bras. Leprol., 37(1/4) :41-49, 1970.
43. McRAE, D. H.; RUSSEL, D. A.; SCOTT, G. C.; VINCIN, D. R.; SHEPARD, C. C. Four year results in the therapeutic trial of acedapsone (DADDS) in the Karimui, New Guinea. Int. J. Leprosy, 40(2) :222-223, 1972.
44. MENON, N. K. Madras study of two once-weekly regimens. Clinical aspects. Proc. Int. Tuberc. Conf., (New York, 1969). Bull. Int. Union Against Tuberc., 43:271-275, 1970.
45. MIGUEZ ALONSO, A. Tratamento especifico. In: BRASIL. Ministério da Saúde. Serviço Nacional de Lepra. Manual de Leprologia. Rio de Ja- neiro, 1960. p.97-118.
46. MOLESWORTH, B. D.; NARAYANASWAMI, P. S.; SIMPSON, I. A. The treatment of lepromatous leprosy with 4:4'-diaminodiphenyl sulfone in oil: findings in 100 cases treated for one year' with a note on the technique of sulfone determinations. Int. J. Leprosy. 17(3) :197-210, 1949.
47. MOTULSKY, A. G. Pharmacogenetics. Progr. Med. Genet., 3:49-74, 1964.
48. ORGANISATION MONDIALE DE LA SANTA. Série de Rapports Techniques. Resistance des parasites du paludisme aux medicaments. Rapport d'un Groupe scientifique de l'OMS. Genève, n.° 296, 1965.
49. ORGANIZACIÓN MUNDIAL DE LA SALUD. Serie de Informes Técnicos. Farmacogenetica. Informe de un Grupo Cientifico de la OMS. Genebra, n.° 524, 1973.
50. OPROMOLLA, D. V. A. First results of the use of rifamycin SV in the treatment of lepromatous leprosy. hit. J. Leprosy, 31 :552, 1963.
51. OPROMOLLA, D. V. A. & ALMEIDA, S. C. Primeiros resultados do trata- mento da lepra com kanamicina. Rev. Bras. Leprol., 37(1/4) :17-39, 1970.
52. OPROMOLLA, D. V. A.; PESSOA-MENDES, J.; SOUZA-LIMA, L. A terra- micina na lepra. Rev. Bras. Leprol., 38(1/4) :1-21, 1965.
53. OPROMOLLA, D. V. A.; SOUZA-LIMA, L.; CAPRARA, G. Rifamycin SV in the treatment of lepromatous leprosy. Lepr. Rev., 86(3) :123-131, 1966.
54. OWEN, J. A.; MACKAY, I. R.; GOT, C. Serum haptoglobins in hepatobiliary disease. Br. Med. J., (5135) :1454-1457, 1959.
55. PETERS, J. H.; GORDON, G. R.; BROWN, P. The relationship between the capacities of human subjects to acetylate isoniazid, sulfanilamide and sulfamethazine. Life Sol., 4:99-107, 1965.
56. PETERS, J. H.; GORDON, G. R.; GHOUL, D. C.; TOLENTINO, J. G.; WALSH, G. P.; LEVY,L. The disposition of the antileprotic drug dapsone (DDS) in Philippine subjets. Am. J. Trop. Med. Hyg., 21:450-457, 1972.
57. PETERS, J. H.; GORDON, G. R.; KARAT, A. B. A.; MEYERS, W. M. Metabolic disposition of dapsone in Indian and African subjects. In: ANNUAL LEPROSY RESEARCH CONFERENCE, 7th, California, 1972 apud Int. J. Leprosy, 40(2) :221-222, 1972.
58. PETERS, J. H.; GORDON, G. R.; LEVY, L.; STORKAN, M. A.; JACOBSON, R. R.; ENNA, C. D.; KIRCHHEIMER, W. F. Metabolic disposition of dapsone in patients with dapsone-resistant leprosy. Am. J. Trop. Med. Hyg., 23:222-230, 1972.
59. PETTIT, J. H. S. & CHIN, J. Does glucose-6-phosphate dehydrogenase defi- ciency modify the course of leprosy or its treatment. Lepr. Rev., 35(4): 149-156, 1964.
60. POVEY, M. S. & HORTON, R. J. Leprosy and blood groups. Lepr. Rev. 37:147-150, 1966.
61. RAMOS E SILVA, J. Sur le traitement de la 16pre, en particulier de l'hypodermite nodulaire lepromateuse recidivante par la griseofulvine. Dermat. Internat., 7:37-42, 1968 apud /nt. J. Leprosy, 37:208, 1969.
62. BEES, R. J. W. Rifampicin as therapy in lepromatous leprosy. Star, 33 (4): 5, 12, 1974.
63. REES, R. J. W.; PEARSON, J. M. H.; WATERS, M. F. R. Experimental and clinical studies on rifampicin in the treatment of leprosy. Br. Med. J., 1:89-92, 1970.
64. SCHWANTES, A. R.; SALZANO, F. M.; CASTRO, I. V.; TONDO, C. V. Haptoglobins and leprosy. Acta Genet. (Basel), 17:127-136, 1967.
65. SHEPARD, C. C. The first decade in experimental leprosy. Bull. World Health Organ., 44(6) :821-827, 1971.
66. SHESKIN, J. Further observation with thalidomide in lepra reactions. Lepr. Rev., 36:183-187, 1965.
67. SLOAN, N. R.; JANO, B.; WORTH, R. M.; FASAL, P.•' SHEPARD, C. C. Repository acedapsone in leprosy chemoprophylaxis and treatment. Lancet, 2:525-526, 1971.
68. SOUZA-LIMA, L. Considerageies sobre o real valor da sulfonoterapia nos pro- gramas de profilaxia da lepra. Rev. Bras. Leprol., 86(1/4) :31-36, 1968/ 1969.
69. SUNAHARA, S.; URANO, M.; LIN, H. T.; CHEG, T. J.•' JARUMILINDA, A. Further observations on trimodality of frequency distribution curve of bio- logically ative isoniazid blood levels and 'cline' in frequencies of alleles controlling isoniazid inactivation. Acta Tuberc. Pneumol. Scand., 43 :181- 195, 1963.
70. SUNAHARA, S.; URANO, M.; OGAWA, M. Genetical and geographic studies on isoniazid inactivation. Science, 134:1530-1531, 1961.
71. TAUSSIG, H. B. A study of the German outbreak of phocomelia. The tha- lidomide syndrome. J. Amer. med. Ass., /80:1106-1113, 1962.
72. TUBERCULOSIS CHEMOTHERAPY CENTRE, Madras. A controlled comparison of a twice-weekly and three once-weekly regimens in the initial treatment of pulmonary tuberculosis. Bull. World Health Organ., 48(1): 143-206, 1970.73. VESELL, E. S. Recent progress in pharmacogenetics. Adv. Pharmacol. Chemother., 7:1-52, 1969.
74. WEINSTEIN, L. Medicamentos utilizados na quimioterapia da lepra e da tuberculose. In: GOODMAN, L. S. & GILMAN, A., ed. As bases farmacológicas da terapêutica. [trad. de Lauro SoHero] 4.a ed. Rio de Janeiro, Guanabara Koogan, 1973. cap. 61, p. 1211-1241.
75. WOLF, M. Dermatitis herpetiformis: response to diaminodiphenylsulfone. Arch. Derm,atol., 82(6) :1020-1021, 1960.
76. WORLD HEALTH ORGANIZATION. Technical Report Series. WHO expert committee on leprosy. Fourth report. Geneva, n.° 459, 1970.
77. YOSHIDA, A. Hemolytic anemia and G6PD deficiency. Science, 179 :532- 537, 1973.
78. ZINKHAM, W. H.; LENHARD JR., R. E.; CHILDS, B. Deficiency of glucose 6-phosphate dehydrogenase activity in erythrocytes from patients with favism. Bull. Johns Hopkins Hosp., 102:169-175, 1958.
Esta revista tiene la licencia Creative Commons Attribution 4.0 International License.
Descargas
Los datos de descargas todavía no están disponibles.
